✦ LIBER ✦

Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer

✍ Scribed by Jonathan I. Epstein; Stephen J. Berry; Joseph C. Eggleston

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 551 KB
Volume: 54
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19841015)54:8<1666::aid-cncr2820540830>3.0.co;2-7

No coin nor oath required. For personal study only.

✦ Synopsis

A measurement of nuclear roundness involving computer-assisted image analysis of histologic specimens was used to predict the prognosis of 19 patients with Stage A2 prostate cancer. This technique accurately identified those tumors that clinically progressed without treatment and those that did not, in contrast to the Gleason grading system, which produced significant prognostic overlap. What separated most of these tumors was the quantification and degree of irregularity of a relatively small subpopulation of cancer nuclei among a majority of rounder nuclei. There are currently several practical limitations in the use of this method, but with improvements in technique and in methods of obtaining tissue, computerized image analysis of nuclear shape may become a valuable tool for analyzing prostate cancer in a quantitative manner, thereby providing valuable information relative to the prognosis of the individual patient.

📜 SIMILAR VOLUMES

Predictors of cancer progression in T1a

Predictors of cancer progression in T1a prostate adenocarcinoma

✍ Liang Cheng; Erik J. Bergstralh; Beth G. Scherer; Roxann M. Neumann; Michael L. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 2 views

## BACKGROUND. The biologic behavior of T1a prostate adenocarcinoma is variable. A critical issue in the management of patients with T1a prostate adenocarcinoma is to distinguish those who will develop cancer progression from those who will not. Predictive factors that identify those at high risk

Prediction of prognosis in untreated sta

Prediction of prognosis in untreated stage A2 prostatic carcinoma

✍ James L. Mohler; Alan W. Partin; Jonathan I. Epstein; Robert L Becker; Ulrika V. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 898 KB

Prognostic factors in stage D2 prostate

Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen

✍ Haim Matzkin; Mark S. Soloway; Paul F. Schellhammer; Gerald Chodak; Joseph A. Sm 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 525 KB

Nuclear factor-κB expression as a novel

Nuclear factor-κB expression as a novel marker of radioresistance in early-stage laryngeal cancer

✍ Kenji Yoshida; Ryohei Sasaki; Hideki Nishimura; Yoshiaki Okamoto; Yoko Suzuki; T 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 482 KB

## Abstract ## __Background.__ The aim of this study was to evaluate the significance of nuclear factor‐kappa B (NF‐κB) expression as a marker of radioresistance in early‐stage laryngeal cancer. ## __Methods.__ Thirty‐five patients with local recurrence and 70 case‐matched patients without local

Polymorphisms of fibroblast growth facto

Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population

✍ Zhiyong Ma; Norihiko Tsuchiya; Takeshi Yuasa; Takamitsu Inoue; Teruaki Kumazawa; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 138 KB 👁 1 views

## Abstract Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand‐induced tyrosine kinase activity. The Glycine (Gly) to Arginine (Arg) polymorphism at codon 388 (Gly388Arg), which encodes an amino acid in the transmembrane part of the FGFR4 gene

Pathologic findings in clinical stage A2

Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage

✍ Wayne N. Christensen; Jonathan I. Epstein; Alan W. Partin; Patrick C. Walsh 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 811 KB

Transurethral resections (TUR) and totally embedded radical prostatectomies from 39 clinical Stage A2 prostate cancers were morphometrically analyzed and compared with 56 prior similarly studied clinical Stage B cancers. All the clinical A2 radical prostatectomies contained residual tumor with 26% h